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Letters to the Editor
1212The quest for the elusive factors that underpin
neutrophil dysfunction in cirrhosis goes one Tritto and colleagues on their recently published
h aimed at extending our understanding of why
rrhosis paradoxically exhibit features of impaired
pacity despite maintaining the ability to generate
nd bystander tissue damage. The neutrophil is a
of the innate immune system and has been
vital role in the development of systemic inﬂam-
n failure in sepsis [2]. The evidence base support-
malfunction in acute and chronic liver disease
ow although factors that underpin this dysfunc-
ear and are likely to be related to a number of
[3–6].
y, Tritto and colleagues explore how the exposure
trophils to plasma from patients with varying
iology of liver disease in vitromay impact on their
rmore, they aimed at investigating what role the
terial DNA, endotoxin and circulating cytokines
ma might play on neutrophil function and Toll-
LR) expression. Lastly, they used a novel aseptic
chnique (blister study) to assess how neutrophils
n 8 patients with Child Pugh A/B alcohol-related
esulting data are both important and insightful
rge that these data need to be interpreted with
stage due to several inherent ﬂaws that exist in
odology.
er clariﬁcation on the control data is warranted.
art of the study, the authors state that age- and
althy volunteers were used as normal controls.
ils are given as to the control demographics or
rols used, which appear to vary signiﬁcantly in
n several ﬁgures in the manuscript. This is critical
phagocytic capacity found in the healthy controls
225,000 geometric mean of ﬂuorescence intensity
ting the neutrophil function within the control
ly variable and making valid statistical compari-
hieve. A number of factors can inﬂuence neutro-
in ‘healthy’ individuals including ethnicity,
habits and exercise within the previous 24 h
be controlled for. This is also fundamental when
interpreting the blister studies, as 3 out of the 5 healthy controls
had reduced phagocytic capacity of a similar magnitude to the
cirrhotic patients and 2 patients stayed the same. This is some-
what at odds with the conclusion that the cirrhotic patients have
impaired neutrophil phagocytic capacity in the blister ﬂuid com-
pared to controls. Moreover, there was a huge variation in GMFI
in the cirrhotic patients (range 25,000–225,000). Four of the eight
patients with cirrhosis also had evidence of impaired phagocytic
capacity in peripheral blood at baseline, clouding the argument
that stable cirrhotic patients did not have impairment of
phagocytic capacity in peripheral blood but did in the inﬂamma-
tory environment.
Secondly, with regard to the TLR data, the baseline expression
of TLR-2, 4 and 9 is not stated prior to exposure to cirrhotic
plasma. This makes it difﬁcult to interpret the impact of the cir-
rhotic plasma on the normal neutrophils. It might also have been
better to have used healthy control plasma rather than phos-
phate-buffered saline which might have signiﬁcantly inﬂuenced
the neutrophil viability and the rate of apoptosis. It would also
be interesting to determine whether the presence or absence of
ascites had any relationship with baseline TLR-4 expression,
which might be expected if this cohort has an increased rate of
gut bacterial translocation.
Lastly, we would be keen to learn more about the cohort
(n = 34) with high oxidative burst. Did a large proportion of these
patients have alcohol-related disease, ascites or encephalopathy?
It is also fascinating to see that these patients had increased lev-
els of IL-12, IFN-gamma and TNF-alpha. IL-12 and IFN-gamma are
not cytokines that are typically associated with neutrophil activa-
tion and may have been released by other immune cell subtypes
such as dendritic cells, macrophages and natural killer cells,
which will undoubtedly have a role to play.
In an ongoing prospective longitudinal cohort study of neu-
trophil morphology, phenotype and function at King’s College
Hospital in over 125 patients with cirrhosis, we have shown
that phagocytic dysfunction is universal in patients with cir-
rhosis (including those with Child Pugh A disease), which is
reversible following liver transplantation [7]. Neutrophil dys-
function is likely to be determined by a large number of vari-
ables including plasma complement, immunoglobulin, sodium
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and ammonia concentrations [8], the presence of hepatic
encephalopathy [9], the presence of ascites and the pro- and
anti-inﬂammatory cytokine milieu [10] which warrant further
investigation. The quest for the elusive factor(s) that underpin
neutrophil function therefore continues.
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Reply to: ‘‘The quest for the elusive factors that underpin
neutrophil dysfunction in cirrhosis goes on’’
To the Editor:
We thank Vijay and colleagues for their appreciation and interest
in our paper evaluating some features of neutrophil dysfunction
in cirrhosis of different severity [1].
They raise three points which are addressed below:
1. The ﬁrst issue raised was over concerns for the high variability
of phagocytic capacity in the group of healthy controls and the
numerous factors inﬂuencing neutrophil function, which may
hinder the statistical evaluation of differences. We used
plasma from 21 healthy controls who were non-smokers and
had not drunk alcohol in the previous 48 h. For cytokine
assays we used 10 healthy controls. With regards to variabil-
ity, we would suggest that it was even higher in the cirrhosis
group, with some patients showing higher phagocytic capacity
than controls. In general, variability is a normal component of
all biologic phenomena and an ever-present bystander in all
experimental models. Statistical methods are speciﬁcally
aimed at evaluating whether the differences between two
groups are secondary to casual variability or not. In this spe-
ciﬁc experiment, despite some overlap of phagocytic capacity
between patients and control, the probability of the null-hyp-
otesis was calculated as less than 1 in 10,000, a quite reassur-
ing value. On the other hand, one may argue that also some
negative results (i.e. accepting the null hypothesis or non-sta-
tistically signiﬁcant differences) can actually be the conse-
quence of high variability. In fact, in our discussion we
focused only on the results supported by strong statistical sig-
niﬁcance. In addition, the observations of Vijay and colleagues
give us the opportunity to stress once again that all patients
with liver cirrhosis are not the same and better understanding
of the reason for such wide variations is needed. It is therefore
remarkable the constant and invariable near to complete loss
of phagocytic capacity of neutrophils migrating to the skin
blisters of cirrhotic patients, indicating that patients with cir-
rhosis have evidence of marked neutrophil dysfunction.
2. The ‘‘control’’ TLR expression in Fig. 4 refers to neutrophils
incubated with healthy control’s plasma as stated in the ‘‘Sub-
jects’’ paragraph and similar to all other experiments as stated
in the Materials and methods section.
3. We found a trend towards higher oxidative burst in patients
with alcoholic aetiology, ascites or encephalopathy (not statis-
tically signiﬁcant). We preferred to focus and comment only
on results supported by strong statistical signiﬁcance.
The preliminary data Vijay et al. refer to are interesting and
we understand consistent with our results. Further understand-
ing of the underlying mechanisms will allow development of
new strategies that can reduce the risk of infection in liver
disease.
JOURNAL OF HEPATOLOGY
Journal of Hepatology 2012 vol. 56 j 1207–1217 1213
